Core Insights - VENU Holding Corporation is redefining ownership in live entertainment through a unique business model that combines upscale venues with premium hospitality and real estate opportunities [3][4] - The company aims to operate 20 venues with a total of 250,000 seats by 2028, with current operations in Colorado Springs and Gainesville, and additional venues under development [7][8] - VENU's non-dilutive growth strategy focuses on protecting shareholder equity by utilizing asset-backed lending and internally generated income, recently securing $200 million in financing [5][10] Business Model - VENU operates a "vertically integrated live entertainment" model, controlling all aspects from real estate to food and beverage operations, which allows for multiple revenue streams [4][9] - The Luxe FireSuites program offers investors ownership opportunities within venues, generating recurring revenue and targeting double-digit annual returns [6][10] - The company leverages Public-Private Partnerships (PPPs) to negotiate land contributions and tax incentives, enhancing economic impact for cities [9] Financial Performance - In 2024, VENU sold $77.7 million in FireSuites, a 250% increase from the previous year, with a target of $200 million in sales for 2025 [8][10] - The company anticipates becoming EBITDA-positive in 2026 and achieving net profitability in 2027, supported by the operational leverage from its business model [13] Market Strategy - VENU targets high-growth secondary markets with strong population trends and limited access to premium live entertainment, such as McKinney and El Paso [12] - The construction timeline for new venues is approximately 12-14 months, with many becoming cash-flow positive in their first full season due to pre-sales and secured naming rights [12] Leadership and Vision - The company emphasizes discipline in leadership, focusing on real assets and recurring income to build a sustainable business [14] - VENU's leadership is committed to long-term growth, with plans for national expansion and new revenue streams under the guidance of newly appointed President of Growth and Strategy, Terri Liebler [14][15]

Core Insights - BrainsWay is launching two new Continuing Medical Education (CME) courses to enhance clinician knowledge and confidence in Transcranial Magnetic Stimulation (TMS) [1][2] - The courses are designed to clarify the differences between BrainsWay's Deep TMS™ technology and first-generation TMS, while providing practical guidance for clinical integration [1][3] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, focusing on its proprietary Deep TMS™ platform technology [5] - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [5] - BrainsWay aims to increase global awareness and access to Deep TMS, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [5] Educational Initiatives - The CME courses are supported by independent educational grants from BrainsWay and offer up to 0.5 AMA PRA Category 1 Credits™ [2] - The courses are accessible online to a wide range of healthcare professionals, including psychiatrists and nurse practitioners [2] - The first course focuses on evidence-based data supporting TMS and its role in mental health treatment, while the second course emphasizes practical strategies for patient identification and treatment integration [6]

Core Insights - Atos successfully delivered a comprehensive suite of digital services, including the AI-powered GAUDI content repository, for the European Youth Olympic Festival (EYOF) Skopje 2025, enhancing efficiency, accessibility, engagement, and security for all stakeholders involved [1][6][8] Digital Services Provided - Atos implemented a cloud-based Entries & Accreditation System that streamlined management processes and registered over 4000 participants across two simultaneous events [2] - The official Skopje 2025 website served as a central portal for event information, including schedules, results, and volunteer details, ensuring comprehensive engagement for visitors [3] - A mobile app was developed to keep users informed with the latest news, competition schedules, and exclusive content, enhancing user experience during the event [4] GAUDI Content Repository Features - GAUDI offers an AI-powered platform for managing and accessing digital content, allowing users to request content through natural language queries and providing ready-to-use video clips [5] - The system automatically generates clips and highlights, creates ready-to-share posts, adapts content for various devices, and integrates photos, enhancing the overall experience for users [6] Company Background and Experience - Atos has over 30 years of experience in serving partners and customers in major events, demonstrating flexibility and technology excellence across various scales of events [8] - The company has been involved with the Olympic Movement since 1992 and is the Official Digital Technology Partner for multiple prestigious sporting events, showcasing its long-standing commitment to the sports industry [9][11]

Core Viewpoint - Moleculin Biotech, Inc. has received a Notice of Intent to Grant for a European patent that will enhance its market position for Annamycin, a potential first non-cardiotoxic anthracycline, aimed at treating hard-to-treat tumors and viruses [2][3][4] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses, with its lead program being Annamycin [5] - Annamycin is designed to avoid multidrug resistance and lacks the cardiotoxicity associated with current anthracyclines, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases [5] Patent and Development - The new European patent will cover methods for creating a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until 2040 [3][4] - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases, as well as Orphan Drug Designation from the EMA [4] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [6] - The development pathway for Annamycin is considered substantially de-risked with input from the FDA [6] Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting various cancers, and a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses and certain cancer indications [7]

Company Overview - Graphjet Technology is an innovative producer of graphene and graphite, founded in 2019 in Malaysia, utilizing patented technology to recycle palm kernel shells into single-layer graphene and artificial graphite [5] Recent Developments - The company successfully received new machinery and equipment at its factory in Malaysia, which is expected to enhance production capabilities significantly [1][2] - A specialist from the supplier is on-site to install and commission the new equipment, with installation expected to be completed within a week [2] Production Capacity and Market Demand - The new machinery is projected to increase production capacity by approximately seven times, aligning with the growing demand for graphite and graphene, particularly in the semiconductor industry [4] - The expansion of advanced semiconductor manufacturing, driven by the demand for specialized chips, presents a favorable market environment for Graphjet [3][4] Strategic Positioning - Graphjet's sustainable production methods using agricultural waste position the company to potentially transform the global graphite and graphene supply chain [5]

Core Insights - Neuronetics, Inc. has published significant findings demonstrating the effectiveness of NeuroStar TMS in treating adolescents and young adults with depression, as reported in a leading medical journal [1][2] Company Overview - Neuronetics is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through innovative products [4] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for major depressive disorder (MDD) and other mental health conditions across the United States [4] Treatment Efficacy - The study based on the NeuroStar TrakStar Clinical Database involved 1,283 patients, with approximately 70% reporting clinically meaningful improvement in depression symptoms, while less than 1% experienced worsening [2][3] - The results for adolescents and young adults align with previous findings in adult populations, indicating a strong correlation between the number of treatment sessions completed and clinical improvement [2] Market Opportunity - With one in five adolescents experiencing major depressive disorder and limited FDA-approved medications available, NeuroStar TMS presents a significant opportunity to provide a safe and effective treatment option for this demographic [3] - Since receiving FDA clearance as an add-on therapy for adolescents aged 15-21 in March 2024, there has been over a one-third increase in the number of adolescents treated with NeuroStar [2]

EXL is a premium Genesys AppFoundry partner, bringing advanced data, AI, and domain expertise to the experience orchestration engineNEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ: EXLS), a global data and AI company, and Genesys®, a global cloud leader in AI-powered experience orchestration, announced a collaboration to transform customer engagement and business operations across industries. By combining EXL’s advanced data, AI and domain expertise with Genesys’ industry-leading Contact Center as a ...

Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE™-1 Phase 1b Clinical Trial of TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Initial Cohort 1 Data for TN-401 and Enrollment of Additional Patients in Both Dose Cohorts Planned for Fourth Quarter of 2025 SOUTH SA ...

Group 1 - Aterian, Inc. will release its financial results for Q2 2025 on August 13, 2025, after market close [1] - A conference call to discuss the results will be held at 5:00 p.m. ET on the same day [1] - Investors can participate in the call via phone or through a live webcast [1] Group 2 - Aterian, Inc. is a consumer products company focused on building and acquiring e-commerce brands across various categories [2] - The company sells products on major online marketplaces such as Amazon, Walmart, and Target, as well as through its own direct-to-consumer websites [2] - Aterian's brand portfolio includes Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct [2]

Core Insights - Obicetrapib significantly reduced plasma p-tau217 levels, a key Alzheimer's disease biomarker, in both the full analysis set and in ApoE4 carriers, indicating its potential as a novel approach to Alzheimer's prevention [1][3][12] - In ApoE4/E4 carriers, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo [1][4] - The results support obicetrapib's cardiometabolic profile, showing reductions in LDL-C and other cardiovascular risk factors [1][2] Company Overview - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C [1][15] - The company aims to address unmet needs in populations where existing therapies are not sufficiently effective or well-tolerated [15] Clinical Trial Details - The BROADWAY trial was a pivotal Phase 3 study designed to evaluate the LDL-C lowering efficacy of obicetrapib in patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia [2][10] - A total of 2,530 patients were randomized to receive either 10 mg obicetrapib or placebo for 52 weeks, with the primary endpoint being the percent change in LDL-C [10][11] Biomarker Analysis - The prespecified analysis evaluated the effect of obicetrapib on plasma biomarkers of Alzheimer's disease in 1,515 patients, including 367 ApoE4 carriers [2][12] - Statistically significant reductions in p-tau217 were observed, with additional favorable trends in other biomarkers such as NFL and GFAP [3][4][12] Implications for Alzheimer's Disease - The findings suggest that upstream lipid modulation may influence Alzheimer's disease risk, particularly in ApoE4 carriers, who represent over 25% of the population [7] - Obicetrapib's ability to reduce multiple important AD biomarkers alongside its LDL-C lowering effects highlights its potential to address both neurodegenerative and cardiovascular disease risks [7][14]